Anaveon, a Basel-based immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the Novartis Venture Fund. The company was founded with financing from BaseLaunch, the healthcare accelerator of BaselArea.swiss in December 2017 and...

The Basel-based biotech company Alentis Therapeutics AG has successfully concluded a CHF 12.5 million Series A financing co-lead by BioMedPartners and BB Pureos Bioventures and joined by BPI France, Schröder Adveq and the HTGF. Alentis develops therapeutics in advanced liver disease and cancer. BaseLaunch, a healthcare accelerator operated by...

Basel-based biopharmaceutical Versameb has raised 6.4 million Swiss francs in a Seed C financing round and will put the funds towards expanding its technology platform. Versameb was supported by the healthcare accelerator program BaseLaunch of BaselArea.swiss in 2017/18. With its latest financing round, Versameb has raised 11.8 million...

ImmunOs Therapeutics AG is a Swiss biotechnology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer. They have recently announced a Series A financing of CHF 15 million, which was co-led by Pfizer Ventures and BioMedPartners. They plan to...